Iaso Therapeutics portfolio includes a variety of vaccines currently in discovery and preclinical development:
IASO-001: A powerful pan-Salmonella vaccine effective against four AMR Salmonella serovars including S. Typhi, S. Paratyphi, S. Enteritidis, and S. Typhimurium
IASO-002: A novel vaccine targeting the cell surface polysaccharide poly-N-acetylglucosamine with potential indications spanning major healthcare issues such as MRSA, urinary tract infections and pneumonia
